Edition:
India

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

7.32USD
6 Dec 2019
Change (% chg)

-- (--)
Prev Close
$7.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
57,295
52-wk High
$17.80
52-wk Low
$5.36

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals Q3 Loss Per Share $0.72
Thursday, 7 Nov 2019 

Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.72.Q3 EARNINGS PER SHARE ESTIMATE $-0.83 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF SEPTEMBER 30, 2019 TOTALED $121.5 MILLION.CONCERT PHARMACEUTICALS- EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS TO BE SUFFICIENT TO FUND CO THROUGH 2020 UNDER CURRENT OPERATING PLAN.  Full Article

Concert Pharma Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM PHASE 2 ALOPECIA AREATA TRIAL.CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM PHASE 2 ALOPECIA AREATA TRIAL.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG AND 12 MG TWICE-DAILY DOSING COHORTS.CONCERT PHARMACEUTICALS INC - ADVANCEMENT INTO PHASE 3 EVALUATION PLANNED IN 2020.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG AND 12 MG TWICE-DAILY DOSING COHORTS.  Full Article

Concert Pharmaceuticals Q2 Loss Per Share $0.78
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q2 LOSS PER SHARE $0.78.Q2 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019, TOTALED $136.6 MILLION.CONCERT PHARMACEUTICALS - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND COMPANY INTO SECOND HALF OF 2020.  Full Article

Concert Pharmaceuticals Q1 Loss Per Share $0.93
Thursday, 2 May 2019 

Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.93.Q1 REVENUE $1.0 MILLION VERSUS $10.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.62 -- REFINITIV IBES DATA.Q1 REVENUE ESTIMATE $5.3 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF MARCH 31, 2019, TOTALED $153.8 MILLION.  Full Article

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS INITIATES PHASE 1 MULTIPLE-ASCENDING DOSE TRIAL OF CTP-692 AS AN ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - TOPLINE DATA FROM BOTH SINGLE-AND MULTIPLE-ASCENDING CTP-692 PHASE 1 TRIALS ARE EXPECTED IN Q2 OF 2019.CONCERT PHARMACEUTICALS INC - CTP-692 WAS FOUND TO BE WELL TOLERATED IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED.  Full Article

Concert Pharmaceuticals Reports Q3 2018 Financial Results
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.74.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.  Full Article

Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing
Thursday, 1 Mar 2018 

March 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING.  Full Article

Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26
Thursday, 1 Mar 2018 

March 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS.CONCERT PHARMACEUTICALS INC - CTP-543 ON TRACK TO REPORT TOPLINE PHASE 2A RESULTS IN ALOPECIA AREATA BY YEAR-END.CONCERT PHARMACEUTICALS INC - NEW NEUROPSYCHIATRIC PRODUCT CANDIDATE POISED TO ENTER CLINICAL DEVELOPMENT IN 2018.CONCERT PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.26.CONCERT PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG COHORTS OF CTP-543 PHASE 2A TRIAL IN Q4 OF 2018.CONCERT PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, TOTALED $203.2 MILLION VERSUS $96.2 MILLION AS OF DECEMBER 31, 2016.CONCERT PHARMACEUTICALS INC - EXPECTS ITS CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DECEMBER 31, 2017 TO BE SUFFICIENT TO FUND COMPANY INTO 2021.  Full Article

Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - PHASE 2A TRIAL ON TRACK TO COMPLETE IN SECOND HALF OF 2018.  Full Article

Concert Pharma Says FDA Granted Fast Track Designation To CTP-543
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Concert Pharmaceuticals Inc ::FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMA SAYS U.S. FDA GRANTED FAST TRACK DESIGNATION FOR CO'S CTP-543.  Full Article